Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes.
about
Interventions for central serous chorioretinopathy: a network meta-analysisInterventions for central serous chorioretinopathy: a network meta-analysisChorioretinal ischemia and angiogenic milieu following photodynamic therapy.One-year results of bevacizumab intravitreal and posterior sub-Tenon injection of triamcinolone acetonide with reduced laser fluence photodynamic therapy for retinal angiomatous proliferation.Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot studyPhase I clinical trial results of verteporfin enhanced feeder vessel therapy in subfoveal choroidal neovascularisation in age related macular degenerationPhotodynamic therapy of experimental choroidal neovascularization in the mouse.Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration.Half-dose verteporfin combined with half-fluence photodynamic therapy for chronic central serous chorioretinopathy.The past, present, and future of exudative age-related macular degeneration treatment.Lucentis using Visudyne study: determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration.Oscillatory photodynamic therapy for choroidal neovascularization and central serous retinopathy; a pilot study.Diagnosis and interventions for central serous chorioretinopathy: review and update.Choroidal thickness outside the laser irradiation area after photodynamic therapy in polypoidal choroidal vasculopathy.Current and emerging treatment options for uveal melanoma.Photodynamic Therapy and Intravitreal Bevacizumab with Versus without Triamcinolone for Neovascular Age-related Macular Degeneration; a Randomized Clinical TrialThe chorioretinal damage caused by different half parameters of photodynamic therapy in rabbits.Long-term efficacy of half-dose photodynamic therapy on chronic central serous chorioretinopathy.Optical coherence tomography in photodynamic therapy for subfoveal choroidal neovascularisation secondary to age related macular degeneration: a cross sectional study.1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathyVerteporfin photodynamic therapy induced apoptosis in choroidal neovascular membranes.Comparing half-dose photodynamic therapy with high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy (the PLACE trial): study protocol for a randomized controlled trial.Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol.Half-dose vs one-third-dose photodynamic therapy for chronic central serous chorioretinopathy.Low-fluence photodynamic therapy combinations in the treatment of exudative age-related macular degenerationEffect of Factor XIII-A G185T Polymorphism on Visual Prognosis after Photodynamic Therapy for Neovascular Macular DegenerationMultiple spots of photodynamic therapy for the treatment of severe chronic central serous chorioretinopathy.Efficacy of half-fluence photodynamic therapy depending on the degree of choroidal hyperpermeability in chronic central serous chorioretinopathy.Angiostatic kinase inhibitors to sustain photodynamic angio-occlusion.Predictive role of C677T MTHFR polymorphism in variable efficacy of photodynamic therapy for neovascular age-related macular degeneration.Subfoveal choroidal thickness after photodynamic therapy in patients with acute idiopathic central serous chorioretinopathyEffects of photodynamic therapy with verteporfin for the treatment of chronic central serous chorioretinopathy: An uncontrolled, open-label, observational studyGenetic predictors of response to photodynamictherapy.Evaluation of verteporfin pharmakokinetics--redefining the need of photosensitizers in ophthalmology.Triamcinolone acetonide suppresses early proangiogenic response in retinal pigment epithelial cells after photodynamic therapy in vitro.Long-term prognostic factors of chronic central serous chorioretinopathy after half-dose photodynamic therapy: A 3-year follow-up study.Video monitoring of neovessel occlusion induced by photodynamic therapy with verteporfin (Visudyne), in the CAM model.Changes of outer retinal microstructures after photodynamic therapy for chronic central serous chorioretinopathy.Photodynamic therapy and central serous chorioretinopathy.Microperimetric evaluation of chronic central serous chorioretinopathy after half-dose photodynamic therapy
P2860
Q24186996-BC8BFA97-5169-4245-BF59-494C74F553D3Q24188115-255881E3-CB95-4956-AA84-DD63AFC25691Q30980461-BB009FD5-71A8-4C81-8F51-82A08894B321Q31092005-5566FA57-C95D-45EB-A753-4D32186E46D0Q33239033-DE63A8A0-B60B-49F9-A2BC-27B711FE016DQ33246808-3734A2FF-D9D7-4E20-BD83-34CB3FF8F18AQ33257172-8995F3CE-7B43-40CC-AF72-6E7422073C7DQ33287060-BF24D87C-9B2D-4F7F-950D-0AD4457C2AB3Q33705962-BAD31A58-F138-4875-8B21-F1DB8C7BC180Q34161956-B76AE26F-C0AF-4C4D-8665-C44AF556D924Q34188239-8B420E93-63E9-44E9-BDA5-791D9FD56247Q34210541-7D038890-F348-4291-8C8D-01A6403B176BQ34334335-6B6C55F6-8BB7-4B2D-A4D6-B3CCEFB2D01BQ34585510-25F9ABA4-6712-4C70-96F1-99843FA986FEQ34655878-3F6623AE-1391-40A0-9BA6-5E1EF6616266Q35087032-6F60CB4B-09D1-491A-AA9C-3ADD10A1FDCAQ35192101-A75D5AAD-7EA2-4ACD-84FC-9256C6A4C279Q35561222-B44CE740-FC66-4E98-BEF2-3BB01A71DAC6Q35592940-6046CAD1-82DD-4C9F-8EE0-C9B526E149B0Q35677770-2AA1D2A6-4112-40DA-A4E5-FFC2E6EAA312Q35762059-85F9813B-9C12-48EA-BB6D-582B910E8FFAQ35782233-329A1954-C13A-4E1B-B16E-C62ABC1603EBQ35869490-5DBC1EC8-6C5C-4329-ACFF-63201E2C955FQ35955614-BDE2F0F7-78CA-4ACB-BDDB-904DA79614D7Q36072398-3D92C473-0FCF-4CE7-945B-2EFA03EBDA00Q36088747-F2EA296C-24C9-4FB4-8565-257ED5723AC8Q36326807-F700ABDD-5C7D-4065-B9DC-E2AD307D1291Q36685488-6DEED31B-0DE0-4CF6-8F0E-7CDFE4DEF029Q37295545-C3102889-9A6B-4ED8-A4EB-F4EC94283A09Q37356525-C201D018-2F6A-435C-84AF-1B1F3F248694Q37478532-947FB170-A4FE-4FCA-8090-47DFACDABF82Q37667426-A9EE0B4E-180C-4EB4-9E44-06B9FBB8241CQ37931236-4C25079A-2BBE-4F7D-A6B2-03FE5FD79A0BQ38023892-39F702B4-0A56-45A9-B353-A33DBF259FF6Q40229459-B5E9A8AA-3043-461B-8CFD-9992C9BF89AAQ41106280-0B5F343A-62D2-47DF-8204-F158CF06DB04Q41278020-012A8E02-7954-4435-9ADC-9AC191AFA115Q41484477-E6502A36-383F-4E29-B29E-439353FA6C49Q41990230-18BF0716-46C8-41A8-B66C-8AA8D0C6D5C3Q42093637-BAF19EFB-7DBC-4B37-BE29-91DD87408B22
P2860
Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes.
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
Dose-related structural effect ...... inal structures of human eyes.
@ast
Dose-related structural effect ...... inal structures of human eyes.
@en
type
label
Dose-related structural effect ...... inal structures of human eyes.
@ast
Dose-related structural effect ...... inal structures of human eyes.
@en
prefLabel
Dose-related structural effect ...... inal structures of human eyes.
@ast
Dose-related structural effect ...... inal structures of human eyes.
@en
P2093
P1476
Dose-related structural effect ...... inal structures of human eyes.
@en
P2093
Arne Viestenz
Gottfried O H Naumann
Horst Laqua
P2888
P304
P356
10.1007/S00417-002-0517-4
P577
2002-08-27T00:00:00Z
P6179
1044778775